Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 30.483
NA - Nord America 9.596
EU - Europa 8.505
SA - Sud America 4.872
AF - Africa 619
OC - Oceania 240
Continente sconosciuto - Info sul continente non disponibili 8
Totale 54.323
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 12.605
US - Stati Uniti d'America 8.269
SG - Singapore 6.069
CN - Cina 4.595
IT - Italia 3.512
BR - Brasile 3.435
HK - Hong Kong 1.844
BD - Bangladesh 1.355
RU - Federazione Russa 835
TR - Turchia 727
MX - Messico 708
FR - Francia 686
KR - Corea 685
DE - Germania 593
ES - Italia 585
IN - India 571
AR - Argentina 473
CA - Canada 430
GB - Regno Unito 385
ID - Indonesia 378
JP - Giappone 356
FI - Finlandia 325
CO - Colombia 286
AU - Australia 219
NL - Olanda 190
EC - Ecuador 188
IQ - Iraq 180
PK - Pakistan 179
SA - Arabia Saudita 174
PL - Polonia 165
AT - Austria 159
CL - Cile 157
ZA - Sudafrica 144
VE - Venezuela 114
PH - Filippine 112
EG - Egitto 108
GR - Grecia 107
PT - Portogallo 103
CH - Svizzera 101
SE - Svezia 100
UA - Ucraina 93
MA - Marocco 88
CZ - Repubblica Ceca 86
PE - Perù 83
PY - Paraguay 71
UZ - Uzbekistan 69
KZ - Kazakistan 68
IL - Israele 61
TN - Tunisia 60
TW - Taiwan 60
DZ - Algeria 59
NO - Norvegia 59
RO - Romania 57
MY - Malesia 55
HU - Ungheria 49
AE - Emirati Arabi Uniti 43
KE - Kenya 43
TH - Thailandia 40
BE - Belgio 37
HR - Croazia 37
MD - Moldavia 36
CR - Costa Rica 35
SK - Slovacchia (Repubblica Slovacca) 35
BO - Bolivia 33
NP - Nepal 33
ET - Etiopia 29
JO - Giordania 29
UY - Uruguay 29
GT - Guatemala 28
AZ - Azerbaigian 27
DO - Repubblica Dominicana 27
IE - Irlanda 26
OM - Oman 24
DK - Danimarca 23
SI - Slovenia 22
JM - Giamaica 21
NZ - Nuova Zelanda 20
LT - Lituania 19
AL - Albania 18
HN - Honduras 18
LB - Libano 18
RS - Serbia 17
SN - Senegal 17
PS - Palestinian Territory 15
GE - Georgia 13
SY - Repubblica araba siriana 13
PR - Porto Rico 12
BY - Bielorussia 11
NG - Nigeria 11
IR - Iran 10
NI - Nicaragua 10
AM - Armenia 9
KG - Kirghizistan 9
LK - Sri Lanka 9
LY - Libia 9
PA - Panama 9
QA - Qatar 9
TT - Trinidad e Tobago 9
AO - Angola 8
BG - Bulgaria 8
Totale 54.183
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 4.026
Hanoi 3.219
Singapore 2.619
Hong Kong 1.775
Hefei 1.647
San Jose 1.209
Milan 934
Ashburn 802
Seoul 639
Chicago 548
Rome 473
Los Angeles 428
Lauterbourg 397
New York 354
Da Nang 350
Haiphong 343
São Paulo 333
Dallas 302
Buffalo 296
The Dalles 293
Ha Long 291
Quận Bình Thạnh 247
Biên Hòa 246
Helsinki 244
Istanbul 225
Hải Dương 210
Beijing 202
Ninh Bình 198
Council Bluffs 191
Thái Nguyên 191
Vũng Tàu 177
Can Tho 173
Melbourne 173
Moscow 168
Rio de Janeiro 150
Bắc Ninh 145
Ankara 142
Madrid 133
Jakarta 123
Bắc Giang 120
Boardman 116
Frankfurt am Main 114
Quận Một 113
Santa Clara 112
Tokyo 110
Phủ Lý 107
Quận Phú Nhuận 106
Naples 105
Mexico City 103
Shanghai 102
Montreal 100
Toronto 96
Bogotá 94
Guangzhou 94
Figino 93
Quận Sáu 88
Turin 80
Thái Bình 79
Vinh 77
Santiago 76
Curitiba 75
Baghdad 74
Quito 74
Barcelona 73
Brasília 73
Lấp Vò 72
Buenos Aires 71
Vienna 71
Riyadh 70
Bologna 69
Quận Tân Phú 69
Belo Horizonte 68
Lang Son 68
London 68
Medellín 68
Paris 68
Uyen Hung 68
Jeddah 66
Điện Bàn 65
Guadalajara 64
Lima 63
Atlanta 62
Karachi 62
Hangzhou 61
Dhaka 59
Porto Alegre 59
Vĩnh Tường 59
Nuremberg 58
Palermo 58
Quận Năm 58
Tashkent 58
Amsterdam 55
Quảng Ninh 55
Thu Dau Mot 55
Manchester 53
Cologne 52
Cairo 51
Bến Tre 50
Quận Bảy 50
Athens 49
Totale 29.222
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 4.068
Classification criteria for autoinflammatory recurrent fevers 2.372
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.371
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 999
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 632
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 546
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 485
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 427
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 418
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 413
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 409
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 406
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 392
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 391
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 387
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 374
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 373
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 372
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 365
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 358
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 350
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 349
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 344
Criteria to define response to therapy in paediatric rheumatic diseases 340
Localized scleroderma in childhood is not just a skin disease 333
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 274
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 267
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 265
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 262
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 255
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 252
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 251
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 250
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 239
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 234
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 228
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 223
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 222
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 222
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 219
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 219
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 218
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 215
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 214
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 211
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 211
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 207
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 204
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 200
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 200
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 197
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 197
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 195
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 191
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 185
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 181
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 180
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 180
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 177
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 176
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 175
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 173
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 173
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 173
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 172
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 168
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 166
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 165
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 164
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 161
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 161
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 160
Adalimumab in Juvenile Rheumatoid Arthritis Reply 160
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 160
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 159
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 157
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 157
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 157
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 156
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 149
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 148
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 147
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 146
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 144
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 143
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 142
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 141
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 141
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 141
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 140
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 138
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 137
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 135
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 131
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate 130
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis 127
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials 127
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 127
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA) 125
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 125
Totale 30.896
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.503
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.503
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202644.632 10.069 7.688 3.113 4.583 1.858 1.286 3.311 1.998 2.212 2.449 2.400 3.665
2026/20271.331 1.331 0 0 0 0 0 0 0 0 0 0 0
Totale 56.006